Views & Analysis | Perspectives on pharma industry issues

R&D

Changing Faces: Pharma and biotech, January 2026

The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO changes at biotech firms.

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

R&D

startup discussion investment ideas visual

Strategies for creating an ecosystem to support early-stage ...

Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations

R&D

Q4 Clinical trials round-up: October to December 2025

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

R&D

Big promises, hard work: What 2026 will demand from pharma

Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.

R&D

Clinical research demands agile CROs

An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

Sales & Marketing

pharmaphorum podcast Episode 243, Lisa Sims, Novartis

On quality data for quality learnings, with Lisa Sims

Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, about personalising learning at scale.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

Digital

Activation of the G protein-coupled GABA B receptor by the agonist baclofen

How GenAI is cracking the toughest targets in drug discovery

Generative AI has the potential to solve for designing effective antibodies for G‑protein coupled receptors (GPCRs).

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Patients

Pills from bottle without label into palm of a man's hand

Meeting the growing demand for animal-free medicines

Pharmaceutical manufacturers have begun, albeit tentatively, to acknowledge and respond to evolving dietary sensibilities.

Patients

How to put out the waiting list fire – and make sure it neve...

NHS waiting lists are like fires that everyone is frantically trying to put out. But however much water we pour on it, the flames keep roaring.

Patients

pharmaphorum with Repronovo's Jean Duvall during JPM2026

Bringing parity to infertility, with Jean Duvall

During JPM2026, pharmaphorum spoke with Jean Duvall, CEO of Repronovo, a company that’s working on new infertility treatments for men and women.

Changing Faces: Pharma and biotech, January 2026

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The long-delayed promise of the microbiome, with Sam Possemi...

From engagement metrics to meaningful experience: Why pharma...

Strategies for creating an ecosystem to support early-stage ...

Q4 Clinical trials round-up: October to December 2025

Big promises, hard work: What 2026 will demand from pharma

Clinical research demands agile CROs

Four reasons pharma is sweeping the Super Bowl despite FDA f...

On quality data for quality learnings, with Lisa Sims

From engagement metrics to meaningful experience: Why pharma...

How GenAI is cracking the toughest targets in drug discovery

Biotech leaders: ‘They're shoving this industry into the arm...

European biopharma at a crossroads

A cancer treatment modality that prioritises QoL, with Ben Z...

Improving breast cancer outcomes in sub-Saharan Africa

Engineering “smarter” cells, with Tim Lu

Meeting the growing demand for animal-free medicines

How to put out the waiting list fire – and make sure it neve...

Bringing parity to infertility, with Jean Duvall

Changing Faces: Pharma and biotech, January 2026

The long-delayed promise of the microbiome, with Sam Possemi...

Strategies for creating an ecosystem to support early-stage ...

Novartis breaks ground on San Diego biomedical R&D site

How to meet your physicians where they are online

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks